

30 September 2010

More Excellent VitroGro® Clinical Results

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced further excellent human results from the Australian clinical trial to evaluate VitroGro® for the treatment of chronic venous leg ulcers.

The clinical results for a further 3 patients show:

- Duration of these venous ulcers prior to treatment with VitroGro®:
1, 4, and 8 months
- Healing achieved with 6 VitroGro® treatments over 24 days:
57%, 46% and 90%

These results bring the Australian human venous ulcer trial to a total of 30 patients. When the clinical data for the last 3 patients are included, the overall trial results for all 30 venous ulcer patients after only 24 days treatment with VitroGro® show:

- Complete healing of 5 out of 30 patients or 16.7%
- Average venous ulcer healing: 43%
- Statistical significance: $p < 0.0001$
- Average patient age: 71 years
- Average duration of venous ulcer prior to joining the VitroGro® trial: 11 months
- Average time venous ulcer unresponsive to compression therapy (the current best practice treatment): 9 months

This data complements the exceptional results produced in the Canadian VitroGro® clinical trial of 10 patients previously announced (ASX: TIS CEO AGM Presentation 27 November 2009) and extends the total VitroGro® human trial experience to 40 patients.

Dr Steven Mercer, the CEO of Tissue Therapies said “VitroGro® has consistently produced excellent results across both the Australian and Canadian human trials. The human data is even better than we expected from more than 8 years of our published scientific work with live human skin.”

“When 20 weeks of conventional treatment leaves up to 50% of diabetic and venous ulcers unhealed, the results achieved with only 6 treatments of VitroGro® over 24 days are remarkable.”^{1,2}

“The clinical data from 40 patients gives us even more confidence in the ability of VitroGro® to fundamentally improve the treatment of chronic wounds with accelerated healing that is safe and predictable and with a cost effectiveness that has not previously been available.”

The human trial results announced today mark the conclusion of this Australian venous ulcer human trial conducted by Professor Michael Stacey at the Vascular Research Laboratory in Western Australia. Professor Stacey and his clinical group have now started their participation as one of the sites in the EU multicentre trial of commercial scale VitroGro®, the data from which will be used for approval for sale.

1 Margolis, DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Healing diabetic neuropathic foot ulcers: are we getting better? Diabet Med. 2005; 22 (2): 172-176

2 Franks PJ, Moffatt CJ. Health related quality of life in patients with venous ulceration: use of the Nottingham health profile. Qual Life Res. 2001;10 (8): 693-700

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com